Eli Lilly's Zepbound beats Novo Nordisk's Wegovy in the first head-to-head trial comparing the two obesity drugs.

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

Get the latest The Cigna Group (CI) stock news and headlines to help you in your trading and investing decisions.

Get the annual and quarterly balance sheet of The Cigna Group (CI) including details of assets, liabilities and shareholders' equity.

Learn about the side effects of weight loss medications like Ozempic, Wegovy, Mounjaro and Zepbound, so you can weigh the risks versus benefits. Stacey Colino and Shanley Chien July 30, 2025 ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device industries. He has written about Covid-19 vaccines, advances in cancer ...

Learn more about how to get Ozempic, including who can take it and where to find it, plus cost issues and the latest safety concerns to know about.

See the latest CVS stock price NYSE: CVS stock rating, related news, valuation, dividends and more to help you make your investing decisions.

Ozempic has become a popular off-label tool to support weight management. Learn what experts say on Ozempic for weight loss, its safety and effectiveness.

See the latest The Cigna Group stock price (CI:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Find information about the Health Care sector and industry performance in the U.S. Track the Health Care performance of the stock sector against the Broad Global Market US Index.